Literature DB >> 17168814

Targeting calmodulin in reversing multi drug resistance in cancer cells.

Y C Mayur1, S Jagadeesh, K N Thimmaiah.   

Abstract

Calmodulin is a Ca2+ binding protein found in many eukaryotic cells. It is one of the most important intracellular mediators of Ca2+-dependant signaling in eukaryotic cells. It regulates diverse processes including mitosis, muscle contraction and nucleotide metabolism by modulating the activity of at least 30 different target enzymes in a calcium-dependant manner. Calmodulin plays an important role in the regulation of processes, such as the assembly and disassembly of microtubules by controlling protein kinase activities, by exerting an indirect influence upon a wide variety of cellular processes. It is observed that multi-drug resistant cells have a greater intracellular concentration of calcium than non-resistant cells which contributes to their increased sensitivity to calmodulin antagonism compared with that of non resistant cells. Calmodulin mediated processes can be effectively inhibited by a variety of pharmacological agents of different chemical structures, eg:The calcium channel blocker verapamil and antipsychotic drugs like the Phenothiazines. Many bioisosteres of phenothiazines like phenoxazines and acridones have been prepared and these have also shown very good calmodulin antagonism. These calmodulin antagonists have been shown to modulate multi-drug resistance (MDR) in cancer cells. This review highlights concepts of identification and optimization of new inhibitors of calmodulin in reversing MDR in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168814     DOI: 10.2174/138955706778993021

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  8 in total

Review 1.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

2.  Regulation of calcium signaling in lung cancer.

Authors:  Haihong Yang; Qi Zhang; Jianxing He; Wenju Lu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

3.  Identification and inhibitory properties of a novel Ca(2+)/calmodulin antagonist.

Authors:  Josep Colomer; Allison A Schmitt; Eric J Toone; Anthony R Means
Journal:  Biochemistry       Date:  2010-05-18       Impact factor: 3.162

4.  Degradation or excretion of quantum dots in mouse embryonic stem cells.

Authors:  Qing Meng Pi; Wen Jie Zhang; Guang Dong Zhou; Wei Liu; Yilin Cao
Journal:  BMC Biotechnol       Date:  2010-05-06       Impact factor: 2.563

5.  Study on preparation, characterization and multidrug resistance reversal of red blood cell membrane-camouflaged tetrandrine-loaded PLGA nanoparticles.

Authors:  Xiao Que; Jing Su; Pengcheng Guo; Zul Kamal; Enge Xu; Siyu Liu; Jieyu Chen; Mingfeng Qiu
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

6.  CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma.

Authors:  Tao Liu; Xiujuan Han; Shutao Zheng; Qing Liu; Aerziguli Tuerxun; Qiqi Zhang; Lifei Yang; Xiaomei Lu
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

7.  The immunosuppressive activities of newly synthesized azaphenothiazines in human and mouse models.

Authors:  Michał Zimecki; Jolanta Artym; Maja Kocieba; Krystian Pluta; Beata Morak-Młodawska; Małgorzata Jeleń
Journal:  Cell Mol Biol Lett       Date:  2009-06-25       Impact factor: 5.787

8.  Acetylation stabilises calmodulin-regulated calcium signalling.

Authors:  Karen Baker; Michael A Geeves; Daniel P Mulvihill
Journal:  FEBS Lett       Date:  2022-02-07       Impact factor: 3.864

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.